# Jean Pierre Arnaud

> Jean Pierre Arnaud is a seed investor backing Biotechnology and Medical. See 2 investments, check sizes, portfolio and contact details. Updated Sep 2026.

- Type: Angel Investor
- Total investments: 2
- Last investment: May 2018
- Lead investor: 0%
- Last updated: Sep 2026

Jean Pierre Arnaud is a seed investor focused on Biotechnology and Medical. Jean Pierre Arnaud received his D.V.M. from the National Veterinary School of Maison-Alfort, France, then got a certificate in Nutrition for food-production animals (CSAAD) and a specialization in poultry production from the National School of Agronomics of Paris-Grignon, he also got a certificate in Statistics from University of Paris VI. Heco-founded Avogadro in May 1998 after having worked ten years at Rhone Merieux/Merial starting as clinician and finally as Manager of the Drug Safety Department.

## Contacts

5 contacts available for Jean Pierre Arnaud: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/jean-pierre-arnaud?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 100% |
| Medical | 1 | 50% |
| Wellness | 1 | 50% |
| Health Care | 1 | 50% |
| Manufacturing | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 50% |
| Private Equity | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Flash Therapeutics | Flash Therapeutics is a new gene therapy company developing gene and cell-based therapies by leveraging its proprietary lentiviral platform. | $3.9M | Private Equity | May 16, 2018 | http://www.flashtherapeutics.com |
| Vectalys | Vectalys, expert in gene delivery based on lentiviral vectors, is a private biotech company founded by Pascale Bouillé in 2005. Today, Vectalys counts 25 full-time employees exclusively dedicated to providing lentiviral vectors, cell models, molecular biology strategies and supporting your projects. Vectalys aims to help scientists worldwideunderstand cellular and molecular mechanisms in order to discover new drugs and therapies. Vectalys has developed a state-of-the-art proprietary technology to provide the highest quality of lentiviral vectors for the transduction of hard-to-transfect cells like primary cells, stem cells and in vivo tissues.Vectalys high quality lentiviral vectors ensure 100% transduction efficiency and non-toxic transduction on any target cells, for example to create predictive models. Because each project is unique, the Vectalys team supports you by providing custom lentiviral vectors for the right application with your gene of interest.Vectalys is also the manufacturer of highly pure ready-to-use lentiviral vectors carrying fluorescent, bioluminescent or gene editing proteins. These products are distributed worldwide. Vectalys is committed to providing solutions that save your time and support your most ambitious projects. | $282.9K | Seed | May 18, 2015 | https://www.vectalys.com/ |

2 of 2 investments shown.

## Co-investors
- [Auriga Partners](https://shizune.co/investors/profile/auriga-partners) — VC Fund, 1 deal together
- [Galia Gestion](https://shizune.co/investors/profile/galia-gestion) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund

### Similar country
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [Kima Ventures](https://shizune.co/investors/profile/kima-ventures) — VC Fund
- [Partech](https://shizune.co/investors/profile/partech) — VC Fund

## Featured in investor lists
- [Biotechnology Angel Investors in France](https://shizune.co/investors/biotechnology-angel-investors-france)
- [Biotech Angel Investors in France](https://shizune.co/investors/biotech-angel-investors-france)
- [Medical Angel Investors in France](https://shizune.co/investors/medical-angel-investors-france)

## FAQ

### What does Jean Pierre Arnaud invest in?

Jean Pierre Arnaud invests primarily in Biotechnology, Medical and Wellness startups, most often at Seed and Private Equity stage. Most of the 2 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Jean Pierre Arnaud?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Jean Pierre Arnaud last invest?

The most recent investment recorded for Jean Pierre Arnaud closed in May 2018. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co